Clinical Cancer Research The Science of Cancer Health Disparities
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilcken, N. R.
Right arrow Articles by Sutherland, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilcken, N. R.
Right arrow Articles by Sutherland, R. L.

Clinical Cancer Research, Vol 3, Issue 6 849-854, Copyright © 1997 by American Association for Cancer Research


ARTICLES

Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens

NR Wilcken, OW Prall, EA Musgrove and RL Sutherland
Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Darlinghurst, New South Wales 2010, Australia.

The development of endocrine resistance in previously sensitive, estrogen receptor-positive breast cancers is a major limitation in the treatment of breast cancer. Because antiestrogens have a cell cycle-specific action on breast cancer cells and influence the expression and activity of several cell cycle-regulatory molecules, the development of aberrant cell cycle control mechanisms is a potential mechanism by which cells might develop resistance to antiestrogens. We postulated that overexpression of cyclin D1, which is a common feature of breast cancer, may confer antiestrogen resistance. We addressed this question in vitro by testing the ability of ectopic cyclin D1 overexpression to overcome the growth-inhibitory effects of tamoxifen and the pure steroidal antiestrogens, ICI 164384 and ICI 182780, in T-47D and MCF-7 human breast cancer cells. In cells stably transfected with a human cyclin D1 cDNA under the control of a metal-inducible metallothionein promoter, cyclin D1 expression was increased 2-4-fold following treatment with zinc. Despite the continued presence of antiestrogen, cyclin D1 induction resulted in the formation of active cyclin D1/Cdk4 complexes, concurrent hyperphosphorylation of the retinoblastoma protein, and entry into S phase of cells previously arrested in G1. Elevated cyclin D1 protein levels were first detected 3 h after treatment with zinc, and the proportion of cells in S phase began to increase 6 h later. The S-phase fraction increased 2-3-fold from 13 to 17% in cells treated with antiestrogen alone, to a peak of 33-38% 15 h after zinc treatment. Both the cyclin D1 protein level and the proportion of cells in S phase increased with increasing concentrations of zinc. We conclude that the ectopic overexpression of cyclin D1 reverses the growth-inhibitory effect of antiestrogens in estrogen receptor-positive breast cancer cells, providing a potential mechanism for clinical antiestrogen resistance.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. Rudas, M. Lehnert, A. Huynh, R. Jakesz, C. Singer, S. Lax, W. Schippinger, O. Dietze, R. Greil, W. Stiglbauer, et al.
Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy
Clin. Cancer Res., March 15, 2008; 14(6): 1767 - 1774.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Ishii, S. Waxman, and D. Germain
Tamoxifen Stimulates the Growth of Cyclin D1-Overexpressing Breast Cancer Cells by Promoting the Activation of Signal Transducer and Activator of Transcription 3
Cancer Res., February 1, 2008; 68(3): 852 - 860.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Loi, B. Haibe-Kains, C. Desmedt, F. Lallemand, A. M. Tutt, C. Gillet, P. Ellis, A. Harris, J. Bergh, J. A. Foekens, et al.
Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade
J. Clin. Oncol., April 1, 2007; 25(10): 1239 - 1246.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. L. Kilker and M. D. Planas-Silva
Cyclin D1 Is Necessary for Tamoxifen-Induced Cell Cycle Progression in Human Breast Cancer Cells
Cancer Res., December 1, 2006; 66(23): 11478 - 11484.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
J. Eeckhoute, J. S. Carroll, T. R. Geistlinger, M. I. Torres-Arzayus, and M. Brown
A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer
Genes & Dev., September 15, 2006; 20(18): 2513 - 2526.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
J-R Weng, C-Y Chen, J J Pinzone, M D Ringel, and C-S Chen
Beyond peroxisome proliferator-activated receptor {gamma} signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 401 - 413.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. Jirstrom, M. Stendahl, L. Ryden, A. Kronblad, P.-O. Bendahl, O. Stal, G. Landberg, and The South Swedish and Southeast Swedish Breast Can
Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification
Cancer Res., September 1, 2005; 65(17): 8009 - 8016.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
B. Chen, H. Pan, L. Zhu, Y. Deng, and J. W. Pollard
Progesterone Inhibits the Estrogen-Induced Phosphoinositide 3-Kinase->AKT->GSK-3{beta}->Cyclin D1->pRB Pathway to Block Uterine Epithelial Cell Proliferation
Mol. Endocrinol., August 1, 2005; 19(8): 1978 - 1990.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. M. Shah, M. Al-Dhaheri, Y. Dong, C. Ip, F. E. Jones, and B. G. Rowan
Selenium disrupts estrogen receptor {alpha} signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells
Mol. Cancer Ther., August 1, 2005; 4(8): 1239 - 1249.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E
Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
O. G. Rodriguez-Mora, M. M. LaHair, J. A. McCubrey, and R. A. Franklin
Calcium/Calmodulin-Dependent Kinase I and Calcium/Calmodulin-Dependent Kinase Kinase Participate in the Control of Cell Cycle Progression in MCF-7 Human Breast Cancer Cells
Cancer Res., June 15, 2005; 65(12): 5408 - 5416.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J.-W. Huang, C.-W. Shiau, Y.-T. Yang, S. K. Kulp, K.-F. Chen, R. W. Brueggemeier, C. L. Shapiro, and C.-S. Chen
Peroxisome Proliferator-Activated Receptor {gamma}-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells
Mol. Pharmacol., April 1, 2005; 67(4): 1342 - 1348.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
H. Zhang, T. McElrath, W. Tong, and J. W Pollard
The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation
J. Endocrinol., January 1, 2005; 184(1): 129 - 140.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
I. Chu, K. Blackwell, S. Chen, and J. Slingerland
The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer
Cancer Res., January 1, 2005; 65(1): 18 - 25.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. P. Alao, E. W-F. Lam, S. Ali, L. Buluwela, W. Bordogna, P. Lockey, R. Varshochi, A. V. Stavropoulou, R. C. Coombes, and D. M. Vigushin
Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor {alpha}-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines
Clin. Cancer Res., December 1, 2004; 10(23): 8094 - 8104.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Balasenthil, A. A. Sahin, C. J. Barnes, R.-A. Wang, R. G. Pestell, R. K. Vadlamudi, and R. Kumar
p21-activated Kinase-1 Signaling Mediates Cyclin D1 Expression in Mammary Epithelial and Cancer Cells
J. Biol. Chem., January 9, 2004; 279(2): 1422 - 1428.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J. Ellis, A. Coop, B. Singh, Y. Tao, A. Llombart-Cussac, F. Janicke, L. Mauriac, E. Quebe-Fehling, H. A. Chaudri-Ross, D. B. Evans, et al.
Letrozole Inhibits Tumor Proliferation More Effectively than Tamoxifen Independent of HER1/2 Expression Status
Cancer Res., October 1, 2003; 63(19): 6523 - 6531.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Hui, G. L. Finney, J. S. Carroll, C. S. L. Lee, E. A. Musgrove, and R. L. Sutherland
Constitutive Overexpression of Cyclin D1 but not Cyclin E Confers Acute Resistance to Antiestrogens in T-47D Breast Cancer Cells
Cancer Res., December 1, 2002; 62(23): 6916 - 6923.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-M. Liu, C. Albanese, C. M. Anderson, K. Hilty, P. Webb, R. M. Uht, R. H. Price Jr., R. G. Pestell, and P. J. Kushner
Opposing Action of Estrogen Receptors alpha and beta on Cyclin D1 Gene Expression
J. Biol. Chem., June 28, 2002; 277(27): 24353 - 24360.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. J. Skildum, S. Mukherjee, and S. E. Conrad
The Cyclin-dependent Kinase Inhibitor p21WAF1/Cip1 Is an Antiestrogen-regulated Inhibitor of Cdk4 in Human Breast Cancer Cells
J. Biol. Chem., February 8, 2002; 277(7): 5145 - 5152.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. A. Musgrove, L.-J. K. Hunter, C. S. L. Lee, A. Swarbrick, R. Hui, and R. L. Sutherland
Cyclin D1 Overexpression Induces Progestin Resistance in T-47D Breast Cancer Cells Despite p27Kip1 Association with Cyclin E-Cdk2
J. Biol. Chem., December 7, 2001; 276(50): 47675 - 47683.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. D. Planas-Silva, J. L. Donaher, and R. A. Weinberg
Functional Activity of Ectopically Expressed Estrogen Receptor Is Not Sufficient for Estrogen-mediated Cyclin D1 Expression
Cancer Res., October 1, 1999; 59(19): 4788 - 4792.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. S. Kenny, R. Hui, E. A. Musgrove, J. M.W. Gee, R. W. Blamey, R. I. Nicholson, R. L. Sutherland, and J. F. R. Robertson
Overexpression of Cyclin D1 Messenger RNA Predicts for Poor Prognosis in Estrogen Receptor-positive Breast Cancer
Clin. Cancer Res., August 1, 1999; 5(8): 2069 - 2076.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
O. W. J. Prall, E. M. Rogan, E. A. Musgrove, C. K. W. Watts, and R. L. Sutherland
c-Myc or Cyclin D1 Mimics Estrogen Effects on Cyclin E-Cdk2 Activation and Cell Cycle Reentry
Mol. Cell. Biol., August 1, 1998; 18(8): 4499 - 4508.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
G. Urban, T. Golden, I. V. Aragon, J. G. Scammell, N. M. Dean, and R. E. Honkanen
Identification of an Estrogen-inducible Phosphatase (PP5) That Converts MCF-7 Human Breast Carcinoma Cells into an Estrogen-independent Phenotype when Expressed Constitutively
J. Biol. Chem., July 13, 2001; 276(29): 27638 - 27646.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
O. W. J. Prall, J. S. Carroll, and R. L. Sutherland
A Low Abundance Pool of Nascent p21WAF1/Cip1 Is Targeted by Estrogen to Activate Cyclin E{middle dot}Cdk2
J. Biol. Chem., November 21, 2001; 276(48): 45433 - 45442.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
R. Lu and G. Serrero
Mediation of estrogen mitogenic effect in human breast cancer MCF-7 cells by PC-cell-derived growth factor (PCDGF/granulin precursor)
PNAS, January 2, 2001; 98(1): 142 - 147.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1997 by the American Association for Cancer Research.